Maven Securities LTD Has $963,000 Stake in Inari Medical, Inc. (NASDAQ:NARI)

Maven Securities LTD raised its position in Inari Medical, Inc. (NASDAQ:NARI) by 33.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,000 shares of the company’s stock after buying an additional 5,000 shares during the quarter. Maven Securities LTD’s holdings in Inari Medical were worth $963,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. NEOS Investment Management LLC acquired a new stake in shares of Inari Medical during the 4th quarter worth approximately $396,000. Point72 Europe London LLP raised its holdings in shares of Inari Medical by 91.8% in the 4th quarter. Point72 Europe London LLP now owns 332,202 shares of the company’s stock valued at $21,567,000 after acquiring an additional 158,997 shares in the last quarter. Clear Street Markets LLC bought a new stake in shares of Inari Medical during the 4th quarter worth $198,000. Vanguard Group Inc. raised its stake in shares of Inari Medical by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock worth $327,086,000 after acquiring an additional 325,586 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its stake in Inari Medical by 462.4% in the 1st quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company’s stock worth $1,491,000 after purchasing an additional 25,566 shares during the period. Institutional investors own 90.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft initiated coverage on Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective on the stock. Stifel Nicolaus initiated coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective on the stock. Truist Financial reaffirmed a “hold” rating and issued a $55.00 price objective (down previously from $60.00) on shares of Inari Medical in a research report on Wednesday, July 31st. Finally, Robert W. Baird reduced their price objective on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a research note on Wednesday, July 31st. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $58.44.

Insider Transactions at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $45.83, for a total value of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares in the company, valued at $29,482,255.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Thomas Tu sold 16,520 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $55.09, for a total value of $910,086.80. Following the completion of the sale, the insider now directly owns 313,257 shares of the company’s stock, valued at approximately $17,257,328.13. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00. Following the completion of the sale, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,520 shares of company stock valued at $6,958,467. 10.60% of the stock is owned by insiders.

Inari Medical Stock Down 1.5 %

Shares of NASDAQ:NARI opened at $40.63 on Wednesday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $69.40. The company has a 50 day moving average of $46.32 and a two-hundred day moving average of $46.12. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of -99.10 and a beta of 1.00.

Inari Medical (NASDAQ:NARI) last announced its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The company had revenue of $145.82 million during the quarter, compared to the consensus estimate of $143.96 million. On average, equities analysts anticipate that Inari Medical, Inc. will post -0.7 earnings per share for the current year.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.